| Literature DB >> 35163450 |
Mari Suzuki1,2, Kazunori Sango1, Yoshitaka Nagai2,3.
Abstract
α-Synuclein (αSyn) plays a major role in the pathogenesis of Parkinson's disease (PD), which is the second most common neurodegenerative disease after Alzheimer's disease. The accumulation of αSyn is a pathological hallmark of PD, and mutations in the SNCA gene encoding αSyn cause familial forms of PD. Moreover, the ectopic expression of αSyn has been demonstrated to mimic several key aspects of PD in experimental model systems. Among the various model systems, Drosophila melanogaster has several advantages for modeling human neurodegenerative diseases. Drosophila has a well-defined nervous system, and numerous tools have been established for its genetic analyses. The rapid generation cycle and short lifespan of Drosophila renders them suitable for high-throughput analyses. PD model flies expressing αSyn have contributed to our understanding of the roles of various disease-associated factors, including genetic and nongenetic factors, in the pathogenesis of PD. In this review, we summarize the molecular pathomechanisms revealed to date using αSyn-expressing Drosophila models of PD, and discuss the possibilities of using these models to demonstrate the biological significance of disease-associated factors.Entities:
Keywords: Drosophila; Parkinson’s disease; α-Synuclein
Mesh:
Substances:
Year: 2022 PMID: 35163450 PMCID: PMC8835920 DOI: 10.3390/ijms23031519
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Advantages of using Drosophila for studying human diseases.
| Advantage | Note |
|---|---|
| (1) Analysis of gene functions in vivo | Encode homologues of more than 75% of human disease genes |
| (2) Rapid generation cycle and short lifespan | 10–14 days from embryo to adult |
| Lifespan of 60–80 days | |
| (3) Well-maintained information | Flybase 1, the leading database for genomic and genetic information of |
| (4) Abundant useful tools for genetic analysis | Genome-wide mutant and RNAi fly libraries |
| Cell-type- and temporal-specific gene expression systems | |
| Genome editing systems | |
| (5) Little labor and cost-effective | Transgenic flies can be established relatively easily at low cost |
| Mutant, RNAi, and transgenic flies are available from public stock centers at low cost | |
| Small space is required for their maintenance |
1 http://flybase.org (accessed on 23 January 2022).
Assays to evaluate PD-associated phenotypes in Drosophila.
| Category of Phenotype | Specific Phenotype Evaluated | Assay |
|---|---|---|
| Behavior | Locomotor dysfunction | Climbing assay, automated tracking systems |
| Abnormal sleep behavior, circadian rhythm | ||
| Olfactory deficits | Odor acuity/discrimination assay | |
| Anxiety | Open-field assay | |
| Cognitive dysfunction | T-maze assay | |
| Lifespan | Lifespan assay | |
| Neurodegeneration | DA neuron loss | Counting DA neurons either by tyrosine hydroxylase staining or reporter expression |
| Compound eye degeneration | Observation of external eye appearance by light microscopy, scanning electron microscopy, or analysis of retina tissue sections | |
| Neuronal dysfunction | Electrical activity of the retina | Electroretinography |
| Electrical activity of brain or motor neurons | Electrophysiological recordings from projection neurons or neuromuscular junction | |
| αSyn accumulation/inclusion formation | αSyn inclusions | Immunohistochemistry with an αSyn antibody |
| αSyn aggregation | Immunoblotting of lysates separated by detergent | |
| Pathological αSyn conformers | Immunohistochemistry with an αSyn antibody after proteinase K (PK) treatment | |
| Immunoblotting of lysates treated with PK | ||
| αSyn oligomers | Biomolecular fluorescence complementation assay |
αSyn-expressing fly lines with modifications for increasing αSyn expression levels.
| Reference | Modifications | Driver Line 1 | Behavior | Histology | Notes |
|---|---|---|---|---|---|
| L.J. Pallanck | Added Kozak sequence (CAAA) and used strains bearing 2 copies of transgenes | DA neurons at PPL1 ↓ (20 days) | 2–5-fold higher αSyn protein level than previously reported lines (Feany [ | ||
| J.M. Shulman | Codon optimization for | Progressive ERG abnormalities (1–30 days) | Retina and photoreceptor degeneration (10–30 days) | 20-fold increase in αSyn protein level than non-codon optimized line | |
| M.B. Feany | Q system | Locomotor dysfunction (>7 days) | Brain vacuolization, cortical neuron ↓ (>10 days) | Using the Q-system yielded higher levels of αSyn than using the GAL4/ |
1 Tissues in which each GAL4 or QF2 driver induces UAS- or QUAS-linked transgene expression are as follows: TH-GAL4, DA neurons; Rh1-GAL4, R1-6 photoreceptor cells; Syb-QF2, pan-neurons. PPL1, protocerebral posterior lateral.
WT or familial mutant αSyn-expressing fly lines and their characterizations.
| Reference | Driver | Behavior | Histology | Notes | |
|---|---|---|---|---|---|
| M.B. Feany | WT | DA neuron ↓ (30–60 days) | |||
| Locomotor dysfunction | DA neuron ↓ (30–60 days) | ||||
| Retinal degeneration (10–30 days) | |||||
| N.M. Bonini | WT | DA neuron ↓ (A30P > A53T > WT, 20 days) | |||
| T. Iwatsubo | WT | Phosphorylation of αSyn at S129 (A53T > A30P > WT) | |||
| G. Mardon | WT | No changes in DA neuron number (30 days) | No changes in DA neuron number were found in the Feany [ | ||
| No changes in locomotor function (up to 38 days) | |||||
| No changes in ommatidial morphology (40 days) | |||||
| S.K. Maji | WT | Locomotor dysfunction (G51D > E46K > WT, H50Q, >30 days) | DA neuron ↓ (30 days) | ||
| Y. Nagai | WT | Mild eye degeneration (1 day) | Site-specific transgenesis to express equivalent transcriptional levels of αSyn | ||
| Locomotor dysfunction (E46K, H50Q, H50Q, and A53T at 3 weeks, all lines at 5 weeks) | E46K αSyn protein accumulation | ||||
| M. Haddadi [ | WT | Irregular organization of ommatidia, loss of bristles (10 days) | |||
| Locomotor dysfunction | DA neuron ↓ (E46K > WT) | ||||
| Short lifespan (E46K) |
1 Tissues in which each GAL4 driver induces UAS-linked transgene expression are as follows: elav-GAL4, pan-neurons; ddc-GAL4, DAand serotonergic neurons; GMR-GAL4, compound eye; nSyb-GAL4, pan-neurons.